Refine your search
Collections
Co-Authors
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Gharge, Deepali
- Pharmacogenomics: An Overview
Abstract Views :196 |
PDF Views:7
Authors
Affiliations
1 Government College of Pharmacy, Karad, Tal. - Karad, Dist. - Satara, 415124, State - Maharashtra, IN
1 Government College of Pharmacy, Karad, Tal. - Karad, Dist. - Satara, 415124, State - Maharashtra, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 1, No 2 (2009), Pagination: 59-65Abstract
To increase the drug response, the pharmacogenomics applicable in pharmacotherapy by studying genomic level of the human being pharmacogenomics examine the role of entire genome in both disease susceptibility and drug response; in an attempt to identify specific genes, human genetic variation RNA and protein expression differences, that are associated with specific diseases and that may be targets for new drugs. Pharmacogenomics show ability to explore not only drug metabolizing polymorphisms but also drug target polymorphism, drug transporter polymorphisms.Many factors influence drug responses including age, gender, body weight, patient health, disease status, diet, smoking, alcohol, and exercise and drug interaction. However despite careful consideration of these factors, there is no guarantee that a given treatment will be effective. It is thought that a major cause for variability in drug responses lies in patient's genetic makeup. Genetic variations can be used to explain inter individual differences in drug response.
Pharmacogenomics is the study of how individual's genetic inheritance affects the body's response to drugs. The term comes from the words pharmacology and genomics and is thus the intersection of pharmaceuticals and genetics.
Pharmacogenomics holds the promise that drugs might one day be tailor-made for individuals and adapted to each person's own genetic makeup. Environment, diet, age, lifestyle, and state of health all can influence a person's response to medicines, but understanding an individual's genetic makeup to be the key to creating personalized drugs with greater efficacy and safety.
Keywords
Pharmacogenomics, Individual's Genetic Inheritance, Genome, Personalized Drugs.References
- Evans WE, Relling MV, Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 1999; 286: 487-491.
- Mancinelli L, Cronin M, Sadee W, Pharmacogenomics: The promise of personalized medicine. AAPS PharmSci, 2000; article 4: 2 (1)
- Johnson JA, Drug target pharmacogenomics. Am J Pharmacogenomics, 2001; 1: 271-281.
- Kalow W, Pharmacogenetics and evolution, Pharmacogenetics 2000; 10: 1-3.
- Leon Shargal et al., Applied Biopharmaceutics and Pharmacokinetics, 2005: 355.
- Michael Silber B, Pharmacogenomics, Biomarkers, and the Promise of Personalized Medicine, in Pharmacogenomics 2001: 14.
- Laurinda BH, Ethical Challenges in the Management of Health Information 2001: 275.
- Leland H, Hartwell et al., Genetics: From Genes to Genomes 2000:113.
- Peyser PA, Burns TL, Khoury MJ et al., Approaches to Quantify the Genetic Component of and Identify Genes for Complex Traits, in Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease 2004: 43.
- Brown SM, Kalow W et. al., Essentials of Medical Genomics, 2003: 253.
- Duret L, Mouchiroud D, Gouy M, Hovergen: a database of homologous vertebrae genes, Nucleic Acids Res, 1994; 22: 2360-2365.
- Health Insurance Portability and Accountability Act, Pub. L. No. 110 Stat, 1936 (1996): 104-191.
- Veenstra DL, The Interface between Epidemiology and Pharmacogenomics, in HUMAN GENOME EPIDEMIOLOGY: A SCIENTIFIC FOUNDATION FOR USING GENETIC INFORMATION TO IMPROVE HEALTH AND PREVENT DISEASE, supra note 8: 234.
- Laviero M et al., Pharmacogenomics: the Promise of Personalized Medicine, 2 AAPS J. 2000; 1, 3, note 7: 201.
- Kenneth R, Miller, Joseph L, Biology, 2000: 75.
- U.S. National Library of Medicine, National Institutes of Health, Department of Health & Human Services, Help Me Understand Genetics (February 25, 2005): 11.
- Hughes HB, Biehl JP, Jones AP, Schmidt LH, Metabolism of isoniazide in man as related to the occurrence of peripheral neuritis. Am Rev Tuberculosis, 1954; 70: 266-273.
- Motulsky AG, Drug reactions, enzymes and biochemical genetics. JAMA, 1957; 165: 835-837.
- Bonicke R, Lisboa BP, Erbeddingtheit der intraindividuellen Konstanz der Isoniazidausscheidung beim Menschen. Naturwissenschaften 1957; 44:314.
- Kalow W, Pharmacogenetics, Heredity and the Response to Drugs. Philadelphia: W. B. Sauders, 1962.
- Hansen TS, Petersen NE, Iitia A, Blaabjerg O, Petersen PH, Roburst non-radioactive oligonucleotide ligation assay to detect a common point mutation in the CYP2D6 gene causing abnormal drug metabolism. Clin Chem, 1995; 41: 413-418.
- Shi MM, Bleavins MR, de la Iglesia FA, Technologies for detecting genetic polymorphism in pharmacogenomics, Mol Diagn, 1999; 4: 343-351.
- Lars N, The Coming Pharmacogenomics Revolution: Tailoring Drugs to Fit Patients' Genetic Profiles, JURIMETRICS J. 2002; 1: 9:43.
- Lazarou J, Pomeranz BH, Corey PN, Incidence of adverse drug reactions in hospitalized patients, JAMA, 1998; 279: 1200-1205.
- Sadee W, Finding the right drug for the right patient. Pharm Res, 1998; 15: 959-963.
- Brookes AJ, The essence of SNPs. Gene, 1999; 234: 177-186.
- Marshall A, Getting the right dug into the right patient. Nat Biotechnol, 1997; 15: 1249-1252.
- McCarthy JJ, Hilfiker R, The use of single-nucleotide polymorphism maps in pharmacogenomics. Nat Biotechnol, 2000; 18: 505-508.
- Veenstra DL, Kollman PA, Modeling protein stability: a theoretical analysis of the stability of T4 lysozyme mutants. Protein Eng, 1997; 10: 789-807.
- Sadee W, Pharmacogenomics. BMJ, 1999; 319: 1-4.
- Israel E, Drazen JM, Ligget SB, et al., The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med, 2000; 162: 75-80.
- Tolle R, Information technology tools for efficient SNP studies. Am J Pharmacogenomics, 2001; 1: 303-314.
- Cambien F, Poirier O, Nicaud V, et al. Sequence diversity in 36 candidate genes for cardiovascular disease. Am J Hum Genet, 1999; 65: 183-191.
- Dawson E, New collaborations make pharmacogenomics a SNP. Mol Med Today 1999; 5: 280.
- Arther ML, Introduction to protein science: Architecture, function and genomics, 2005: 25.
- Francke U, Foellmer BE, The glucocorticoid receptor gene is in 5q-q32. Genomics, 1989; 4: 610-612.
- Anderson NG, Anderson L, The human protein index. Clin Chem, 1982; 28: 739-748.
- Collins FS, The human genome project and the future of medicine.Ann NY Acad Sci, 1999; 882: 42-65.
- Pfost DR, Boyce-Jacino MT, Grant DM, A SNPshot: pharmacogenetics and the future of therapy. Trends Biotechnol, 2000; 18: 334-338.
- Burger's Medicinal Chemistry and Drug Discovery, Sixth Edition, Volume 4: 618-632.
- Roses AD, Pharmacogenomics and practice of medicine nature. 2000; 405: 857-865.
- Hoffman PC, Lung cancer. Lancet, 2000; 355: 479.
- Lazarou J, Pomeranz BH, Corey PN, Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies, JAMA, 279(15), Apr 1998; 15: 1200-5.
- Hodgson J, Marshall A, Pharmacogenomics: will the regulators approve? Nature Biotechnology, 1998; 16: 243-246.
- Pistoi S, Facing your genetic destiny, part II. Scientific American. February 2002: 25.
- Lee W, Lockhard C, Kim RB, Rothenberg ML, Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development, 2005; 10: 104-111.
- Lennard L, Gibson BE, Nicole T, Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child, 1993; 69: 577-579.
- Sayers I, Hall IP, Pharmacogenetic approaches in the treatment of asthma. Curr Allergy Asthma Rep, 2005; 5: 101-108.
- I. Zineh, T. Gerhard, C.L.Aquilante, A.L.Beitelshees, B.N.Beasley, A.G. Hartzema, Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs. The Pharmacogenomics Journal.2004:354-358.
- Wang HY, Luo M, Tereshchenko IV, et al., A genotyping system capable of simultaneously analyzing >1000 single nucleotide polymorphisms in a haploid genome. Genome Res, 2005;15:276-283.
- Kalow W, Meyer Urs A, Tyndale RF, Pharmacogenomics, 2008:135-140.
- Schafer A, Hawkinsan JR, DNA variation and the future of human genetics. Nature biotech 1998;16:33-39.
- Proteomics: A Tool in Future
Abstract Views :190 |
PDF Views:0
Authors
Affiliations
1 Government College of Pharmacy, Karad, Dist -Satara-415124, M.S., IN
2 Govt. College of Pharmacy, Karad, IN
1 Government College of Pharmacy, Karad, Dist -Satara-415124, M.S., IN
2 Govt. College of Pharmacy, Karad, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 1, No 3 (2009), Pagination: 99-103Abstract
Scientists are very interested in proteomics because it gives a much better understanding of an organism than genomics. First, the level of transcription of a gene gives only a rough estimate of its level of expression into a protein. Whole Genome Sequence gives complete proteins contain, but does not show how proteins function or biological processes occur. Proteomics gives large-scale study of proteins, particularly their structures and functions. Proteomics is a term in the study of genetics which refers to all the proteins expressed by a genome; proteomics involves the identification of proteins in the body and the determination of their role in physiological and pathphysiological functions. The term "proteomics" was coined to make an analogy with genomics, the study of the genes. The word "proteome" is a blend of "protein" and "genome". Proteomics technologies are of major three types Expression Proteomics, Structural Proteomics, Functional Proteomics. Proteomics is applied in various fields like Tumor Metastasis, renal disease diagnosis, Neurology etc. But proteomic technologies hold great promise in the search for clinically useful protein biomarkers for the early detection, diagnosis and prognosis of cancer and for monitoring response to therapy.Keywords
Proteomics, Genomics, Genome, Proteome.References
- Simon R., et al ,"Investigating the correspondence between transcriptomic and proteomic expression profiles using coupled cluster models". Bioinformatics. 2008, 24 : 2894-2900. doi:10.1093/bioinformatics/btn553. PMID 18974169.
- Vikas D, et al.. "New frontiers in proteomics research: A perspective". International Journal of Pharmaceutics.2005,299:1-18.
- Buckingham, Steven 5. "The major world of microRNAs". Micrornas 2003, 01-14
- Anderson N, Anderson N.. "Proteome and proteomics: new technologies, new concepts, and new words". Electrophoresis 1998,19 :1853-61.
- Blackstock W, Weir M. "Proteomics: quantitative and physical mapping of cellular proteins". Trends Biotechnol. 1999, 17 : 121-7.
- P. James. "Protein identification in the post-genome era: the rapid rise of proteomics.". Quarterly reviews of biophysics.1997,30: 279-331.
- Marc R. Wilkins,. "From Proteins to Proteomes: Large Scale Protein Identification by Two-Dimensional Electrophoresis and Arnino Acid Analysis". Nature Biotechnology.1996, 14 : 61-65.
- Wilkins, Marc R., et al. New Frontiers in Functional Genomics. Proteome Research New York: Springer-Verlag, 1997.
- Belhajjame, K. et al. Proteome Data Integration: Characteristics and Challenges. Proceedings of the UK e-Science All Hands Meeting, ISBN 1-904425-53-4, September 2005, Nottingham, UK.
- Liebler DC. Introduction to proteomics: tools for the new biology. 2002, 7: 89603-992.
- Wilkins MR, Williams KL, Appel RD, Hochstrasser DF. Proteome Research: New Frontiers in Functional Genomics , Principles and Practice. 1997, 3-540-62753-7.
- Twyman RM. Principles Of Proteomics .Advanced Text Series. 2004, 1-85996-273-4.
- Fuchs, Jurgen, and Maurizio Podda, editors. Encyclopedia of Medical Genomics and Proteomics. New York: Dekker, 2005
- Aebersold R., Mann M. Mass Spectrometry-Based Proteomics. Nature.2003, 422: 198-207.
- Zhu, W., et al. 'Detection of Cancer-Specific Markers Amid Massive Mass Spectral Data.' Proceedings of the National Academy of Sciences . 2003,100: 14666-71.
- Zhu H, et al. Global analysis of protein activities using proteome chips. Science . 2001,293:2101-2105
- Arora PS,.Comparative evaluation of two two-dimensional gel electrophoresis image analysis software applications using synovial fluids from patients with joint disease. J Orthop Sci 2005,10,2: 160-6
- Jorg von Hagen, VCH-Wiley Proteomics Sample Preparation. 2008,978-3-527-31796-7
- Westermeier, R. and T. Naven.. Proteomics in practice: a laboratory manual of proteome analysis. 2002, 3-527-30354-5.
- Hye A, Lynham S, Thambisetty M, et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain. 2006,129 ,Pt 11: 3042-50.
- Perroud B, Lee J, Valkova N, et al. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer. 2006. 5: 64.
- Yohannes E, et al . Proteomics analysis identifies molecular targets related to diabetes mellitus-associated bladder dysfunction. Mol. Cell Proteomics. 2008,7: 1270-85.
- Rogers M, et al.. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neuralnetwork analysis: identification of key issues affecting potential clinical utility. Cancer Res. 2003, 63: 6971-83.
- Vasan R., Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation . 2006, 113 : 2335-62.
- Weaver R., Molecular biology , 3rd ed, New York: McGraw-Hill. 2005.
- Karp N, et al, Impact of replicate types on proteomic expression analysis. Journal of proteome research. 2005, 4:1867-71
- Karp N, Lilley KS., Maximising sensitivity for detecting changes in protein expression: experimental design using minimal CyDyes,. Proteomics. 2005 , 5:3105-15.
- Martins D, et al., The untiring search for the most complete proteome representation: reviewing the methods, Brief Funct Genomic Proteomic. 2008, 7:312-21.
- Dobrovetsky E, et al., A robust purification strategy to accelerate membrane proteomics. Methods. 2007, 41:381-7.
- Watson J., Towards fully automated structure-based function prediction in structural genomics: a case study. J Mol Biol. 2007, 13;367:1511-22.
- Norin M, Sundström M..Structural proteomics: developments in structure-to-function predictions,Trends Biotechnol. 2002 , 20:79-84.
- Yakunin A., et al, Structural proteomics: a tool for genome annotation. Curr Opin Chem Biol. 2004, 8:42-8.
- Frederic C., Functional Proteomics Mapping of a Human Signaling Pathway. Genome Res.,2004,14: 24-1332.
- Cai Z, Chiu JF, He QY. Application of proteomics in the study of tumor metastasis. Genomics Proteomics Bioinformatics. 2004, 2:152-66.
- Nancy Denslow,et al., Application of Proteomics Technology to the Field of Neurotrauma. Journal of Neurotrauma. 2003, 20: 401-407.